Jiagan Huang

Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Transarterial Chemoembolization Combined with Regorafenib and PD-1 Inhibitor as Second-Line Therapy for Unresectable Hepatocellular Carcinoma.

Transarterial Chemoembolization Combined with Regorafenib and PD-1 Inhibitor as Second-Line Therapy for Unresectable Hepatocellular Carcinoma.

Journal: Cancer management and research

Published: November 17, 2025

Downregulated Expression of Serum Exosome-Derived miR-375-3p Alleviates Interface Hepatitis and Promotes Fibrosis Regression in Patients With Chronic Hepatitis B.

Downregulated Expression of Serum Exosome-Derived miR-375-3p Alleviates Interface Hepatitis and Promotes Fibrosis Regression in Patients With Chronic Hepatitis B.

Journal: Clinical and translational gastroenterology

Published: September 29, 2024

Global temporal trends and projections of hepatitis B-related cirrhosis among adolescents and young adults from 1990 to 2035: an analysis based on the global burden of disease study 2021.

Global temporal trends and projections of hepatitis B-related cirrhosis among adolescents and young adults from 1990 to 2035: an analysis based on the global burden of disease study 2021.

Journal: Frontiers in public health

Published: September 10, 2024

Population Sensitive to Lenvatinib Plus Anti-PD-1 for Unresectable Hepatocellular Carcinoma Infected with Hepatitis B Virus.

Population Sensitive to Lenvatinib Plus Anti-PD-1 for Unresectable Hepatocellular Carcinoma Infected with Hepatitis B Virus.

Journal: Journal of hepatocellular carcinoma

Published: March 09, 2023

Age independent survival benefit for patients with small hepatocellular carcinoma undergoing percutaneous cryoablation: A propensity scores matching study.

Age independent survival benefit for patients with small hepatocellular carcinoma undergoing percutaneous cryoablation: A propensity scores matching study.

Journal: Frontiers in oncology

Published: October 17, 2022

Response Stratification in the First-Line Combined Immunotherapy of Hepatocellular Carcinoma at Genomic, Transcriptional and Immune Repertoire Levels.

Response Stratification in the First-Line Combined Immunotherapy of Hepatocellular Carcinoma at Genomic, Transcriptional and Immune Repertoire Levels.

Journal: Journal of hepatocellular carcinoma

Published: June 24, 2021

The expression level and diagnostic value of microRNA-22 in HCC patients.

The expression level and diagnostic value of microRNA-22 in HCC patients.

Journal: Artificial cells, nanomedicine, and biotechnology

Published: February 25, 2020

The expression level and clinical significance of lncRNA X91348 in hepatocellular carcinoma.

The expression level and clinical significance of lncRNA X91348 in hepatocellular carcinoma.

Journal: Artificial cells, nanomedicine, and biotechnology

Published: July 28, 2019

MicroRNA-3163 targets ADAM-17 and enhances the sensitivity of hepatocellular carcinoma cells to molecular targeted agents.

MicroRNA-3163 targets ADAM-17 and enhances the sensitivity of hepatocellular carcinoma cells to molecular targeted agents.

Journal: Cell death & disease

Published: July 04, 2019

Characterization of Gut Microbiota, Bile Acid Metabolism, and Cytokines in Intrahepatic Cholangiocarcinoma.

Characterization of Gut Microbiota, Bile Acid Metabolism, and Cytokines in Intrahepatic Cholangiocarcinoma.

Journal: Hepatology (Baltimore, Md.)

Published: November 15, 2018

Showing 1-10 of 10

Last Updated: 09/26/2026